Sep 11 |
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
|
Sep 11 |
BridgeBio stock slides on discontinuation of CAH gene therapy
|
Sep 11 |
BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine
|
Sep 10 |
BridgeBio gets FDA RMAT status for Canavan disease gene therapy
|
Sep 10 |
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
|
Sep 10 |
BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
|
Sep 4 |
BridgeBio draws bullish view at Piper on potential acoramidis nod
|
Aug 31 |
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
|
Aug 30 |
Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug
|
Aug 30 |
Alnylam tumbles, BridgeBio gains after heart drug data
|